2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

2:30PM-4:00PM: Abstract Number: 3115

Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy V: Immunogenecity

2:30PM-4:00PM: Abstract Number: 3126

Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Neuropsychiatric Lupus

2:30PM-4:00PM: Abstract Number: 3103

Carbamylated Human Albumin Is One of the Target Antigens of Anti-Carbamylated Protein Antibodies

Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

2:30PM-4:00PM: Abstract Number: 3087

Cell Bound Complement Activation Products in Multianalyte Assay with Algorithm Have Utility in Distinguishing Primary Fibromyalgia from Systemic Lupus Erythematosus

Fibromyalgia: Clinical Issues

2:30PM-4:00PM: Abstract Number: 3118

Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis - CoMorbidities

2:30PM-4:00PM: Abstract Number: 3092

Deficiency of Adenosine Deaminase Type II – Expanding the Clinical Spectrum

Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases

2:30PM-4:00PM: Abstract Number: 3093

Development and Validation of Diagnostic Criteria for Cryopyrin Associated Periodic Syndromes

Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases

2:30PM-4:00PM: Abstract Number: 3099

Differential Effects of IL-6 Blockade Tocilizumab and TNF Inhibitors on the Reduced Angiogenesis and Lining Layer Degeneration in Synovial Tissues from Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

2:30PM-4:00PM: Abstract Number: 3094

Dose Adjustment of Anakinra (Kineret®) Based on Clinical Response in Patients with Severe Cryopyrin-Associated Periodic Syndromes

Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases

2:30PM-4:00PM: Abstract Number: 3145

Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study

Vasculitis III

2:30PM-4:00PM: Abstract Number: 3144

Efficacy and Safety of Tocilizumab for Polymyalgia Rheumatica

Vasculitis III

2:30PM-4:00PM: Abstract Number: 3141

Endothelial Cells Regulate Proinflammatory T Cell Responses in Large Vessel Vasculitis Via NOTCH-NOTCH Ligand Interactions

Vasculitis III

2:30PM-4:00PM: Abstract Number: 3130

Epstein-Barr Virus Induces Activation of Infammatory Markers Via the TLR8 Transduction Pathway in Infected Scleroderma Monocytes

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

2:30PM-4:00PM: Abstract Number: 3089

Evaluation of Learned Helplessness, Perceived Self-Efficacy and Functional Capacity in Patients with Fibromyalgia and Rheumatoid Arthritis

Fibromyalgia: Clinical Issues

2:30PM-4:00PM: Abstract Number: 3123

Evidence of Altered Blood Brain Barrier Permeability in Systemic Lupus Erythematosus Using Magnetic Resonance Imaging

Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Neuropsychiatric Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].